Women with rheumatoid arthritis face roughly twice the odds of preterm birth and giving birth to infants small for gestational age, according to a French prospective multicentre cohort study published in the journal RMD Open.
Pregnancies in women with rheumatoid arthritis remain at increased risk of preterm delivery and foetal growth restriction despite contemporary disease management strategies, Hospital Healthcare Europe reported. Rheumatoid arthritis is a chronic inflammatory disease that commonly affects women during their reproductive years.
While earlier research based on broad population data has noted elevated probabilities of negative pregnancy results, much of this work predates modern therapeutic approaches for rheumatoid arthritis. Investigators therefore aimed to determine the current prevalence of these adverse outcomes among patients with rheumatoid arthritis and to pinpoint contributing factors.
The study subjects were recruited for the French Research Group on Pregnancy and Rare Diseases project over the period spanning 2015 to 2021. Outcomes were compared with pregnancies from the 2016 and 2021 French national perinatal surveys.
Analysis of Rheumatoid Arthritis Pregnancies
The researchers analysed 100 pregnancies in 90 women with rheumatoid arthritis. The average age of the mothers was 33.7 years, and 57.6% of the pregnancies for which parity information was obtainable involved women who had not previously given birth.
During pregnancy, 46% received glucocorticoids and 39% biologic disease-modifying antirheumatic drugs. Of the 39 biologic-exposed pregnancies, all but one involved a tumour necrosis factor inhibitor (TNFi).
A total of 90 pregnancies fulfilled the criteria to be compared against 359 control pregnancies from the wider population. Matching was based on maternal age group, parity, residential area and singleton or multiple pregnancy.
Rheumatoid Arthritis Increases Preterm Delivery and Growth Risks
- Double the Risk: Pregnant women with rheumatoid arthritis face approximately twice the statistical probability of preterm delivery compared to the general population.
- Growth Restrictions: Infants born to mothers with this condition show a significantly higher rate of being small for gestational age, particularly at lower growth percentiles.
- Medication Factors: Higher systemic glucocorticoid doses of 10 mg/day or more during pregnancy show an independent association with preterm birth risks.
Preterm Birth and Small for Gestational Age Rates Increase
Among women with rheumatoid arthritis, 14 of 88 births (15.9%) were preterm, compared with 8.4% in the matched general population. This corresponds to approximately twice the odds of preterm birth (OR 2.08, 95% CI 1.04–4.09).
Seventeen out of 83 pregnancies (20.5%) resulted in births that were small for gestational age below the 10th percentile, versus 39 out of 358 among the control group (10.9%; OR 2.11, 95% CI 1.12–3.94). Regarding the third-percentile benchmark, the respective frequencies were 6.0% and 2.0% (OR 3.21, 95% CI 1.13–9.44).
No statistically significant differences were observed for several other outcomes, including gestational diabetes, caesarean delivery or macrosomia. Researchers then examined factors linked to the two adverse outcomes that occurred more often in women with rheumatoid arthritis.
| Pregnancy Outcome | Rheumatoid Arthritis Cohort (%) | General Population Controls (%) | Odds Ratio (OR) & 95% CI |
|---|---|---|---|
| Preterm Birth | 15.9% (14/88) | 8.4% | OR 2.08 (1.04–4.09) |
| Small for Gestational Age (<10th percentile) | 20.5% (17/83) | 10.9% (39/358) | OR 2.11 (1.12–3.94) |
| Small for Gestational Age (<3rd percentile) | 6.0% | 2.0% | OR 3.21 (1.13–9.44) |
Multivariable Analysis of Associated Risk Factors
According to multivariable modelling, nulliparity showed an independent link to births that were small for gestational age (adjusted OR 3.61, 95% CI 1.08–8.54). Furthermore, preterm delivery showed independent associations with older maternal age (adjusted OR 1.14 per year, 95% CI 1.02–1.27) and the use of systemic glucocorticoids at a minimum of 10 mg/day during gestation (adjusted OR 4.91, 95% CI 1.30–10.59).
Clinical status, evaluated via the Disease Activity Score in 28 joints with C-reactive protein, demonstrated no significant correlation with either of the investigated outcomes. No increased risk was found with tumour necrosis factor inhibitor exposure.
However, the authors cautioned that residual confounding by indication could not be excluded. Higher-dose glucocorticoid use may also identify women with more severe or refractory disease.
The researchers noted several study constraints, such as the relatively limited size of the cohort, the fact that care was mostly provided in tertiary facilities and the existence of significant gaps in trimester-specific data regarding disease activity. Nevertheless, they concluded that pregnancies in women with rheumatoid arthritis remain at increased risk of preterm birth and small for gestational age birth despite advances in treatment.
In order to enhance pregnancy results, the researchers pointed to the importance of prioritising the use of pregnancy-safe biologic treatments and methods to reduce glucocorticoid reliance.
References
- Hamroun S et al. Evaluation of pregnancy outcomes in patients with rheumatoid arthritis compared with the general population: results from a French national prospective and matched study. RMD Open 2026; Jul 8;12(3):e006922.